Reduction of the cetrorelix dose in a multiple-dose antagonist protocol and its impact on pregnancy rate and affordability: A randomized controlled multicenter study.

Dawood AS, Algergawy A, Elhalwagy A

Clinical and experimental reproductive medicine31 Dec 2017Cited by 3 (Europe PMC)

PMID29376021PMCIDPMC5783921DOI10.5653/cerm.2017.44.4.232PepBankPUB-29376021

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In fertility patients, cetrorelix doses did not differ significantly in FSH requirements (2,350.43±150.76 versus 2,366.25±140.34 IU, p=0.548).
In plain wordsIn fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in FSH requirements.
Peptide
Cetrorelix
Outcome
No significant changeRecombinant FSH requirement
Study
n = 123
Comparator
Cetrorelix 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.125 mgAs given in this study (human).
Measurements
FSH requirement
2350.43 IU
0.125 mg
FSH requirement
2366.25 IU
0.25 mg
Source sentences
Summary
The dose of recombinant follicle-stimulating hormone units required was 2,350.43±150.76 IU in group I and 2,366.25±140.34 IU in group II, which was not a significant difference (p=0.548).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly allocated into two groups: group I (n=61) received 0.125 mg of cetrorelix (the study group), and group II (n=62) received 0.25 mg of cetrorelix (the control group).
Report a problemFND-2937602101
02HumanRandomized controlled trialEfficacy outcome
In fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in stimulation duration, retrieved oocytes or developed embryos.
In plain wordsIn fertility patients, cetrorelix doses did not differ significantly in stimulation duration, retrieved oocytes or developed embryos.
Peptide
Cetrorelix
Outcome
No significant changeStimulation duration, retrieved oocytes and developed embryos
Study
n = 123
Comparator
Cetrorelix 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.125 mgAs given in this study (human).
Source sentences
Summary
The duration of stimulation, number of retrieved oocytes, and number of developed embryos were not significantly different between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly allocated into two groups: group I (n=61) received 0.125 mg of cetrorelix (the study group), and group II (n=62) received 0.25 mg of cetrorelix (the control group).
Report a problemFND-2937602102
03HumanRandomized controlled trialEfficacy outcome
In fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in clinical pregnancy rates.
In plain wordsIn fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in clinical pregnancy rates.
Peptide
Cetrorelix
Outcome
No significant changeClinical pregnancy rate
Study
n = 123
Comparator
Cetrorelix 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.125 mgAs given in this study (human).
Source sentences
Summary
The clinical and ongoing pregnancy rates likewise did not significantly differ.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly allocated into two groups: group I (n=61) received 0.125 mg of cetrorelix (the study group), and group II (n=62) received 0.25 mg of cetrorelix (the control group).
Report a problemFND-2937602103
04HumanRandomized controlled trialEfficacy outcome
In fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in ongoing pregnancy rates.
In plain wordsIn fertility patients, cetrorelix 0.125 mg and 0.25 mg did not differ significantly in ongoing pregnancy rates.
Peptide
Cetrorelix
Outcome
No significant changeOngoing pregnancy rate
Study
n = 123
Comparator
Cetrorelix 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.125 mgAs given in this study (human).
Source sentences
Summary
The clinical and ongoing pregnancy rates likewise did not significantly differ.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly allocated into two groups: group I (n=61) received 0.125 mg of cetrorelix (the study group), and group II (n=62) received 0.25 mg of cetrorelix (the control group).
Report a problemFND-2937602104
05HumanRandomized controlled trialEfficacy outcome
In fertility patients, cetrorelix 0.125 mg reduced ICSI cycle costs versus 0.25 mg (US $494.66±4.079 versus US $649.677±43.637).
In plain wordsIn fertility patients, cetrorelix 0.125 mg reduced ICSI cycle costs compared with 0.25 mg.
Peptide
Cetrorelix
Outcome
DecreaseICSI cost per cycle
Study
n = 123
Comparator
Cetrorelix 0.25 mg
Outcome group
Treatment Costs · Reproductive and sexual health
Studied dose
0.125 mgAs given in this study (human).
Measurements
Cycle cost
494.66 US dollars
0.125 mg
Cycle cost
649.677 US dollars
0.25 mg
Source sentences
Summary
The cost of intracytoplasmic sperm injection per cycle was significantly lower in group I than in group II (US $494.66±4.079 vs. US $649.677±43.637).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly allocated into two groups: group I (n=61) received 0.125 mg of cetrorelix (the study group), and group II (n=62) received 0.25 mg of cetrorelix (the control group).
Report a problemFND-2937602105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.